FDA Forges Ahead On Reform Of Drug Ads' Risk Disclosures

Law360, New York (January 12, 2015, 3:08 PM EST) -- The U.S. Food and Drug Administration on Monday said it will re-evaluate how prescription drug risks are disclosed in television advertisements, a significant endeavor that's being closely watched by Big Pharma and consumer groups.

The FDA first proposed its study nearly a year ago, and the agency on Monday confirmed that it plans to proceed, albeit with an approach that has evolved in response to concerns expressed by drugmakers.

At issue is whether TV ads under current regulations are required to talk too much about possible side effects. Regulators say they're worried that information overload may scare away viewers from potentially...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!